Indiaâ€™s life sciences tech company, Indegene Limited has filed draft prospectus with SEBI to seek approval to raise around Rs 3200 crore through initial public offer (IPO).
As per DRHP, the IPO includes fresh issue of equity shares worth Rs 950 crore and an offer for sale of 36,291,497 equity shares by promoters and investors. The selling shareholders in the issue include Carlyle, the Nadathur family office backed by Infosys co-founder Nadathur S Raghavan, Brighton Park Capital and the promoter group.
The net proceeds from the issue will be used to repay debt of its subsidiary, ILSL Holdings; to fund capital expenditure requirements, general corporate purposes and inorganic growth amongst other aspects.
Kotak Mahindra Capital (the left lead), Citi, JP Morgan and Nomura are the merchant bankers working on the IPO. Link Intime Pvt Ltd is the registrar.
Incorporated in 1998, Indegene Limited offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.
Invest wise with Expert advice
The US Federal committee's meeting will conclude on March 16, 2022.
No Record Found